Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells

Anti-Cancer Drugs

Volumn 13, Issue 8, 2002, Pages 869-874

  Boivin, Anne Julie ^a   Momparler, Louise F ^a   Hurtubise, Annie ^a   Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

5 Aza 2 deoxycytidine; Antitumor effect; DNA methylation; Histone deacetylation; Phenylbutyrate

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARYLBUTYRIC ACID DERIVATIVE; DNA; HISTONE; HISTONE ACETYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA HISTONE INTERACTION; DNA METHYLATION; DNA STRUCTURE; DNA SYNTHESIS INHIBITION; DRUG ACETYLATION; DRUG EFFICACY; DRUG POTENTIATION; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; NUCLEOSOME; PRIORITY JOURNAL; SURVIVAL TIME; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DNA, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; LUNG NEOPLASMS; PHENYLBUTYRATES; TUMOR CELLS, CULTURED;

EID: 0036746906     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200209000-00013     Document Type: Article

References (23)

1. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-41.
2. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-7.
3. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000; 183: 145-54.
4. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-96.
5. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210-6.
6. Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16 protein induction by 5-aza-2′-deoxycytidine. Oncogene 1995; 11: 1211-6.
7. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-30.
8. Cote S, Sinnett D, Momparler RL. Demethylation by 5′-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor β gene in human colon carcinoma cells. Anti-Cancer Drugs 1998; 9: 743-50.
9. Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukaemia. Leuk Res 1981; 5: 453-62.
10. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anti-Cancer Drugs 1997; 8: 358-68.
11. Gore SD, Carducci MA. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Invest Drugs 2000; 9: 2923-34.
12. Warrel Jr RP, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621-5.
13. Carducci MA, Nelson JB, Chan-Tack KM, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996; 2: 379-87.
14. Pelidis MA, Carducci MA, Simons JW. Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. Int J Oncol 1998; 12: 889-93.
15. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-91.
16. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-9.
17. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999; 99: 451-4.
18. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-7.
19. Bovenzi V, Momparler RL. Antineoplastic action of 5-aza-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells. Cancer Chemother Pharmacol 2001; 48: 71-6.
20. Valeriote F, Lin H. Synergistic interaction of anticancer drugs. Cancer Chemo Ther Rep 1975; 59: 895-9.
21. Momparler RL. In vitro systems for the evaluation of combination chemotherapy. Pharmacol Ther 1980; 8: 21-5.
22. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst 2000; 92: 1303-7.
23. Momparler RL, Ayoub J. Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001; 34: SIII-5.